Imaging of Corneal Neovascularization: Optical Coherence Tomography Angiography and Fluorescence Angiography

Matthias Brunner,1,2 Vito Romano,1,2 Bernhard Steger,3 Riccardo Vinciguerra,1,2 Samuel Lawman,2 Bryan Williams,2 Nicholas Hicks,1 Gabriela Czanner,2,4 Yalin Zheng,2 Colin E. Willoughby,1,2 and Stephen B. Kaye1,2

1Department of Corneal and External Eye Diseases, St. Paul’s Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
2Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom
3Department of Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria
4Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, United Kingdom

Correspondence: Vito Romano, St. Paul’s Eye Unit, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK; vito.romano@gmail.com.
MB and VR are joint first authors.
Submitted: April 11, 2017
Accepted: February 8, 2018


PURPOSE. The purpose of this study was to compare optical coherence tomography angiography (OCTA) and indocyanine green angiography (ICGA) for the assessment of corneal neovascularization (CoNV).

METHODS. Patients with CoNV extending at least 3 mm into the cornea were included. All patients underwent corneal imaging at the same visit. Images were recorded using the AngioVue OCTA system (Optovue, Inc.) with the long corneal adaptor module (CAM-L). ICGA images were recorded with fluorescent filters using the Heidelberg system (HRA2 Scanning Laser Ophthalmoscope; Heidelberg Engineering). Images were graded for quality by two independent observers. Vessel parameters: area, number, diameter, branch and end points, and tortuosity, were compared between devices. Bland-Altman plots were used to assess differences between parameters.

RESULTS. Fifteen patients with CoNV predominantly associated with microbial keratitis were included. Mean subjective image quality score was better for ICGA (3.3 ± 0.9) than for OCTA (2.1 ± 1.2, P = 0.002), with almost perfect interobserver agreement for ICGA images (κ = 0.83) and substantial agreement for OCTA images (κ = 0.69). Agreement of grading of all investigated vessel parameters between ICGA and OCT images was slight to moderate, with significant differences found for vessel diameter (−8.98 μm, P = 0.01, 95% limits of agreement [LOA]: −15.89 to −2.07), number of branch (25.93, P = 0.09, 95% LOA: −4.31 to 56.17), and terminal points (49, P = 0.05, 95% LOA: 0.78 to 97.22).

CONCLUSION. Compared with ICGA, current OCTA systems are less precise in capturing small vessels in CoNV complexes, and validation studies are needed for OCTA segmentation software. OCTA, however, complements ICGA by providing evidence of red blood cell flow, which together with depth information, may be helpful when planning treatment of CoNV.

Keywords: corneal imaging, cornea neovascularization, optical coherence tomography angiography, fluorescence angiography, indocyanine green angiography

The human cornea in its healthy state is an avascular tissue, with the dynamic balance between pro- and antiangiogenic factors actively maintained by the inhibition of immune and inflammatory events.1 A wide range of inflammatory, infectious, degenerative, and traumatic disorders may disturb this balance and lead to corneal neovascularization (CoNV). CoNV is associated with vision loss and is one of the main causes of corneal blindness, representing a major public health burden in developed countries.1,2 In the United States, the prevalence of CoNV is 4% in the general population, and the incidence per year is 1.4 million patients.3 CoNV also carries a risk of reduced graft survival following a corneal transplant.4,5

Fluorescence angiography was recognized as a useful tool for the evaluation of diseased corneal vessels four decades ago.6 With the advent of new imaging systems and analytical processes, it has gained growing popularity in the clinical assessment of CoNV.7–12 The combined use of fluorescein and indocyanine green angiography (FA and ICGA) has demonstrated better vessel delineation compared with biomicroscopy findings, particularly for vessels beneath areas of corneal scarring.7 In conjunction with objective computer-assisted image analysis, FA and ICGA provide a reliable method for assessing CoNV, such as the measurement of multiple vessel parameters and vessel maturity.13 Comparing CoNV quantitatively is a key requirement for guiding and evaluating treatment.13 Nevertheless, fluorescence angiography remains an invasive imaging technique, which is not only time-consuming and examiner dependent, but although rare, also carries the risk of adverse reactions, such as nausea and anaphylactic reactions.14

Optical coherence tomography (OCT) is a well-established noninvasive imaging technique that generates high-resolution
volumetric (three-dimensional) structural images. The axial resolution of the OCT image data is achieved by measuring the time of flight of light by utilizing its interference with light sent down a separate reference path. In early clinical OCT systems, this was done in time domain (TD) by scanning a mirror in the reference arm relative to the sample. When the reference path length matches a signal from the sample an interference pattern is generated. Modern clinical OCT systems are axially resolved in the Fourier domain (FD), which improves signal-to-noise ratio (SNR). In this case, the reference mirror is fixed, and the light is measured as a function of its frequency. The Fourier transform of the measured spectrum then gives the axialy resolved signal. The lateral resolution of image data in current clinical OCT systems works in the same way as laser scanning confocal microscopy (LSCM), with a single image spot being laterally scanned across the sample. The three-dimensional data acquired by OCT can be used to reconstruct an en face view of coronal sections. OCT is also able to produce functional images of motion by measuring small changes between consecutive measurements. Quantification of blood flow by Doppler OCT has been studied since the early days of OCT. There are several methods of doing this including the Doppler shift of the interference fringes in TD systems and changes in the pixels Fourier phase between consecutive measurements in FD systems. The technical challenges in implementing such precise quantitative systems in a clinical environment, however, is likely to be the main factor in why it has not emerged commercially. The problem can be simplified to a near binary problem of just identifying where there is significant flow rather than trying to get an absolute measure of it. This is known as OCT-angiography (OCTA) and can be implemented by identifying areas where the OCT signal amplitude varies between consecutive images. OCTA has recently started emerging for clinical application.

A major reason for this is the development of more robust processing methods, such as adding split spectrum decorrelation analysis that splits a FD signal into multiple lower axial resolution spectral bands before construction of separate OCT images for each band. The signal de-correlation between consecutive measurements is calculated for each band and then averaged. This gives a higher SNR of flow detection, which increases the methods robustness. Current clinical OCTA instruments are designed specifically for the retina due to the prevalence and clinical importance of blood vessels within its structure. The use of OCTA for ocular surface vessel analysis is currently at a clinical experimental stage.

The aim of this study was to evaluate and compare OCTA with fluorescence angiography for the evaluation of CoNV.

**PATIENTS AND METHODS**

Patients with clinically evident CoNV on biomicroscopy were prospectively recruited from the Department of Corneal and External Eye Disease, Royal Liverpool University Hospital, United Kingdom, between July and August 2016. Only one eye of each patient was investigated. In patients with bilateral CoNV, the eye with more extensive disease on biomicroscopy was imaged. Inclusion criteria were the presence of CoNV extending at least 3 mm into the cornea, with or without corneal scarring, infiltrate or oedema.

Exclusion criteria were less than 18 years of age, contradictions to undergoing ICGA such as allergies to iodine or shellfish, renal failure, or pregnancy, or the inability to fixate on a target due to blindness and/or continuous eye movements such as nystagmus. All patients underwent imaging (OCTA and ICGA) during the same visit. Demographics and clinical data (age, sex, involved eye, diagnosis, best-corrected visual acuity [BCVA], location and duration of CoNV, and previous treatment) were included. The location of CoNV was assessed on slit-lamp biomicroscopy and was defined as superficial if vessels invaded the cornea in the anterior third of the corneal stroma and deep if vessels occurred in the mid and posterior third of the corneal stroma. The study received an Institutional Review Board approval from the ethical committee of The Royal Liverpool and Broadgreen University Hospital and was conducted according to the ethical standards set out in the 1964 Declaration of Helsinki, as revised in 2000. All patients provided informed consent.

**OCTA**

Images were recorded using the AngioVue OCTA system (Optovue, Inc., Fremont, CA, USA) with the long corneal adaptor module (CAM-L) as previously described. The device uses a light source centred on 840 nm and a bandwidth of 45 nm, giving an axial resolution of 5 μm in tissue. The lateral beam width is 22 μm and lateral sampling is 20 μm. The A-scan rate is 70,000 per second. The device measures a three-dimensional scan cube of 6 × 6 × 2.3 mm. The images are processed using a split-spectrum amplitude de-correlation angiography (SSADA) algorithm.

After correct positioning of the patient at the device, three to six corneal scans were performed for each eye using the manual defocusing method and the AngioRetina scan mode. Following instructions from the instruments’ manufacturer and in line with previous studies, the autofocus function was deactivated. After turning down the background illumination, the cornea adaptor lens was then moved toward the corneal surface by advancing the joystick until the corneal tissue appeared in the OCT window (approximately 2 to 3 cm). The focal lengths were manually specified by adjusting the manual F and Z settings (approximately –14 and +14 diopters [D]) until the vessels in the ROI were clearly in focus. Patients were instructed to fixate the target during the image acquisition and avoid blinking or eye movements during the scanning process.

**ICGA**

ICGA images were recorded with fluorescent filters before angiography, as red free, infrared, and fluorescent filters using the Heidelberg system (HRA2 Scanning Laser Ophthalmoscope; Heidelberg Engineering, Heidelberg, Germany) using a 15°, 20°, or 30° lens with a lens focus between 32 and 55 D. Following administration of 3 mL ICG, videography was undertaken for 60 seconds (early phase), commencing 10 seconds after the injection.

**Image Analysis**

The OCTA and ICGA images were independently graded for the appearance of dye in ICGA images and vessel visibility in OCTA images by two masked observers (VR and RV) using a subjective image quality score (0 to 4) as previously published (0 = no vessel discernible, 1 = poor vessel delineation, 2 = good vessel delineation, 3 = very good vessel delineation, 4 = excellent vessel delineation). For the OCTA images, the signal strength index (SSI) was recorded (Optovue uses a proprietary SSI to indicate the signal strength [image quality] of OCT scans on a scale from 0 to 100 [higher is better]). The best ICGA (late frames with complete filling of afferent and efferent vessels) and OCTA images were selected and exported in BMP format for the purpose of semiautomated quantitative image analysis.

In a first step, the pixel resolution (mm/pixel) of the selected ICGA images was defined by using the corneal...
Corneal Neovascularization: ICGA and OCTA

Figure 1. Diagram showing the vessel parameters. In the diagram, branch points $Bl$ are represented by green circles and end points $El$ by red circles. Vessel segment $Si$ is the vessel between either two branch points or between a branch point and an end point. In the diagram, there are five branch points, nine end points, and 12 segments. For each segment, the diameter of a vessel segment is defined as the average diameter measured along its path. The number of pixels belonging to vessels is used to estimate the area of vessels. Please note, in this diagram, vessel pixels are in black and background is in white for the best print effect.

Performing a computer (configurations: Windows 7 Service Pack 1 [Microsoft Corporation, Redmond, WA, USA], Intel Xeon CPU E5 [Intel Corporation, Mountain View, CA, USA], 3.0 GHz, and 32 GB of RAM). For demarcation and depth localization of CoNV on cross-sectional OCTA scans, the cornea was divided into an anterior, mid-, and posterior portion. A scale bar was added to the images by dividing the corneal thickness at the apex into three sections of equal height.

Statistical Analysis

Quantitative measurements were reported as mean ± SD and minimum, median, and maximum. Boxplots were used to assess normality of data. Wilcoxon rank-signed tests were used to test for differences. $P$ values of less than 0.05 were considered statistically significant. Bland-Altman plots were used to assess agreement between vessel parameter measurements of OCTA and ICGA images and the mean of those observed differences, with 95% limits of agreement (LOA) and with 95% confidence interval for LOA are reported. 22, 26 Cohen’s $\kappa$ statistic was used to test the levels of agreement between the image quality scores from two observers.

RESULTS

Seventeen patients were recruited. Two patients were excluded due to poor gaze fixation and resultant poor quality OCTA images. Fifteen patients (median age, 61 years; range, 29 to 78 years; male-to-female ratio, 8:7) were included with a mean duration of CoNV of 35 ± 41.7 months (median, 18 months; range, 3 to 141 months). The patient demographics and clinical features are summarized in Table 1.

Nine eyes had apparent superficial CoNV and six eyes deep CoNV demonstrated by OCTA (Fig. 3). The mean total vessel area of CoNV was larger using ICGA compared with OCTA ($P = 0.02$) and in only 53% of cases (8 of 15) did the OCTA capture all of the CoNV area. The mean subjective quality scores for ICGA and OCTA images were $3.3 \pm 0.9$ and $2.1 \pm 1.2$ ($P = 0.002$), respectively (Fig. 4). Interobserver agreement for the image quality scores was almost perfect for ICGA images (weighted Cohen’s $\kappa = 0.85$) and substantial for OCTA images (weighted Cohen’s $\kappa = 0.69$). The mean signal strength index for OCTA images was $26.4 \pm 9.8$ (min-max, 7 to 42). The signal strength index was poorer in eyes with corneal scarring ($P = 0.002$) and deep CoNV ($P = 0.008$), compared with those without scarring and superficial vessels (Fig. 5A). The image quality score in eyes with CoNV plus scarring and eyes with deep CoNV was found to be significantly better using ICGA compared with OCTA ($P = 0.009$ and $P = 0.03$, respectively).

Overview images of the entire cornea could only be acquired with ICGA due to the limited field of view with OCTA (Fig. 5B).

An overview of the vessel parameter measurements is summarized in Table 2. Higher values were measured for all parameters obtained from ICGA images compared with OCTA images, except for the mean vessel diameter, which was significantly higher in OCTA images (40.75 vs. 49.73 μm, $P = 0.01$). Significant differences were also found for the number of terminal points (119.27 vs. 70.27, $P = 0.01$). The mean differences and limits of agreement are outlined in Table 3. Significant mean differences (measurement bias) were found...
for vessel diameters (8.98 μm, \( P = 0.01 \), 95% LOA, 15.89 to 2.07), number of branch points (25.93, \( P = 0.05 \), 95% LOA 4.31 to 56.17), and number of terminal points (49, \( P = 0.05 \), 95% LOA 0.78 to 97.22), when comparing ICGA and OCTA images. The variability of the total number of vessels increased with increasing number of vessels (see Supplementary Data: Bland-Altman plots).

### DISCUSSION

Both the quantitative and qualitative assessment of CoNV are prerequisites for disease monitoring and planning of treatment. The biomicroscopic assessment of CoNV, although very useful, has several limitations for identifying and quantifying CoNV, especially in the presence of scarring. Previous reports have demonstrated that fluorescence angiography (ICGA) not only allows better vessel delineation than biomicroscopy but provides information on the vessel maturity of CoNV and also enables the differentiation between afferent and efferent vessels, which is critical for the planning of treatment such as selective vessel occlusion with fine needle diathermy.\(^7\)\(^8\)\(^13\)

OCTA is an emerging and promising new technique for noninvasive angiographic imaging. It detects blood vessels by the temporal variances in amplitude and/or phase of the OCT signal due to movement of red blood cells.\(^28\)\(^29\) Current commercial available OCTA systems have been designed for retinal vessel analysis and have been successfully used in the assessment of various vascular pathologies of the posterior segment.\(^2\)\(^3\)\(^4\)

See Figure 2 for vessel depth location on OCTA. Deep CoNV vessels located in mid to posterior third the stroma on biomicroscopy; F, female; FND, fine needle diathermy; HSK, herpes simplex keratitis; LSCD, limbal stem cell deficiency; M, male; NPL, no perception of light; OD, right eye; OS, left eye; PK, penetrating keratoplasty; superficial CoNV, vessels in the subepithelim and anterior third of stroma, on biomicroscopy.

* All patients received topical steroids before and after FND treatment.

![Figure 2](https://example.com/figure2.png)

**Figure 2.** (1A) ICGA. (1B) OCTA. (2A) Segmentation of ICGA. (2B) Segmentation of OCTA.

**Table 1.** Patient Demographics and Clinical Data

<table>
<thead>
<tr>
<th>Patient No. (Sex, Laterality)</th>
<th>Age (y)</th>
<th>Diagnosis</th>
<th>Duration of CoNV (mo)</th>
<th>Area of CoNV (Quadrants)</th>
<th>Location of CoNV</th>
<th>Corneal Scarring</th>
<th>Treatment for CoNV*</th>
<th>BCVA (logMAR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (F, OS)</td>
<td>35</td>
<td>Rosacea keratitis</td>
<td>&gt;6</td>
<td>1</td>
<td>Superficial</td>
<td>Yes</td>
<td>FND</td>
<td>0.2</td>
</tr>
<tr>
<td>2 (F, OD)</td>
<td>79</td>
<td>LSCD</td>
<td>&gt;6</td>
<td>4</td>
<td>Superficial and deep</td>
<td>No</td>
<td>Topical steroids</td>
<td>1</td>
</tr>
<tr>
<td>3 (F, OD)</td>
<td>54</td>
<td>HSK</td>
<td>&gt;6</td>
<td>1</td>
<td>Superficial</td>
<td>Yes</td>
<td>Topical steroids</td>
<td>0.8</td>
</tr>
<tr>
<td>4 (F, OD)</td>
<td>61</td>
<td>HSK</td>
<td>&gt;6</td>
<td>2</td>
<td>Superficial and deep</td>
<td>Yes</td>
<td>FND</td>
<td>0.8</td>
</tr>
<tr>
<td>5 (F, OD)</td>
<td>69</td>
<td>HSK</td>
<td>&gt;6</td>
<td>3</td>
<td>Superficial and deep</td>
<td>Yes</td>
<td>FND</td>
<td>0.6</td>
</tr>
<tr>
<td>6 (M, OS)</td>
<td>68</td>
<td>LSCD</td>
<td>&gt;6</td>
<td>2</td>
<td>Superficial</td>
<td>No</td>
<td>Topical steroids</td>
<td>0.2</td>
</tr>
<tr>
<td>7 (M, OS)</td>
<td>62</td>
<td>PK (corneal dystrophy)</td>
<td>&gt;6</td>
<td>2</td>
<td>Superficial</td>
<td>No</td>
<td>FND</td>
<td>0.2</td>
</tr>
<tr>
<td>8 (M, OS)</td>
<td>71</td>
<td>Rosacea keratitis</td>
<td>&gt;6</td>
<td>1</td>
<td>Superficial</td>
<td>Yes</td>
<td>FND</td>
<td>0.3</td>
</tr>
<tr>
<td>9 (F, OD)</td>
<td>39</td>
<td>HSK</td>
<td>&gt;6</td>
<td>1</td>
<td>Superficial</td>
<td>Yes</td>
<td>Topical steroids</td>
<td>0.1</td>
</tr>
<tr>
<td>10 (M, OD)</td>
<td>46</td>
<td>Rosacea keratitis</td>
<td>&gt;6</td>
<td>2</td>
<td>Superficial and deep</td>
<td>Yes</td>
<td>FND</td>
<td>0.3</td>
</tr>
<tr>
<td>11 (M, OS)</td>
<td>62</td>
<td>HSK</td>
<td>&gt;6</td>
<td>1</td>
<td>Superficial and deep</td>
<td>Yes</td>
<td>Topical steroids</td>
<td>1.0</td>
</tr>
<tr>
<td>12 (F, OD)</td>
<td>62</td>
<td>LSCD</td>
<td>&gt;6</td>
<td>1</td>
<td>Superficial and deep</td>
<td>Yes</td>
<td>Topical steroids</td>
<td>NPL</td>
</tr>
<tr>
<td>13 (M, OD)</td>
<td>31</td>
<td>PK (graft rejection)</td>
<td>3–6</td>
<td>1</td>
<td>Superficial</td>
<td>No</td>
<td>Topical steroids</td>
<td>0.3</td>
</tr>
<tr>
<td>14 (M, OD)</td>
<td>52</td>
<td>PK, HSK</td>
<td>3–6</td>
<td>2</td>
<td>Superficial</td>
<td>No</td>
<td>Topical steroids</td>
<td>0.2</td>
</tr>
<tr>
<td>15 (M, OS)</td>
<td>29</td>
<td>Contact lens-related</td>
<td>3–6</td>
<td>1</td>
<td>Superficial</td>
<td>No</td>
<td>None</td>
<td>-0.1</td>
</tr>
</tbody>
</table>

* All patients received topical steroids before and after FND treatment.
Corneal Neovascularization: ICGA and OCTA

Table 2. Summary of Vessel Parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>ICGA Mean (SD)</th>
<th>Min, Max (Med)</th>
<th>OCTA Mean (SD)</th>
<th>Min, Max (Med)</th>
<th>P Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total vessel area (mm²)</td>
<td>1.92 (1.40)</td>
<td>0.25, 4.17 (1.85)</td>
<td>1.65 (2.68)</td>
<td>0.10, 9.52 (0.61)</td>
<td>0.10</td>
</tr>
<tr>
<td>Number of vessels (n)</td>
<td>123.67 (77.24)</td>
<td>20, 267 (119)</td>
<td>83.53 (95.09)</td>
<td>9, 320 (44)</td>
<td>0.08</td>
</tr>
<tr>
<td>Branch points (n)</td>
<td>69.40 (42.63)</td>
<td>11.68, 142 (68)</td>
<td>43.47 (52.01)</td>
<td>4, 180 (18)</td>
<td>0.06</td>
</tr>
<tr>
<td>Terminal points (n)</td>
<td>119.27 (81.50)</td>
<td>25, 299 (98)</td>
<td>70.27 (67.43)</td>
<td>8, 232 (41)</td>
<td>0.01</td>
</tr>
<tr>
<td>Mean vessel diameter (μm)</td>
<td>40.75 (9.70)</td>
<td>23.30, 57.80 (39.80)</td>
<td>49.73 (14.72)</td>
<td>25.40, 77.70 (48.40)</td>
<td>0.01</td>
</tr>
<tr>
<td>Mean vessel tortuosity</td>
<td>1.11 (0.05)</td>
<td>1.10, 1.30 (1.10)</td>
<td>1.09 (0.05)</td>
<td>1.00, 1.20 (1.10)</td>
<td>0.20</td>
</tr>
</tbody>
</table>

n = 15 eyes.

* Wilcoxon nonparametric signed-rank test.

Figure 4. (1–3A) ICGA images (20° lens, focus 32 D) of CoNV secondary to herpes simplex keratitis (Table 1, patient 3, 1A) and rosacea keratitis (Table 1, patients 8 and 10, 2A and 3A). (1–3B) Corresponding OCTA images (6 × 6-mm scan size) of the same eyes.

Figure 5. (1–3A) Vascularized corneal scar in an eye of a 35-year-old female patient with rosacea keratitis (Table 1, patient 1). Red free OCT image (1A), OCTA (6 × 6-mm scan size, 2A), and ICGA (0.17-03, 20° lens, 32 D focus, 2C). (1–3B) A 79-year-old female patient with limbal stem cell deficiency and 360° of CoNV (Table 1, patient 2). Color image (1B), ICGA (1.02.22, 30° lens, 32 D focus, 2B), and OCTA (6 × 6-mm scan size; 3B). Note the comparably small field width in the OCTA image.
validated for anterior segment OCT (AS-OCTA). Although the software we used has been validated and shown to be robust and accurate for corneal ICG and fluorescein angiography, validation studies for AS-OCTA for CoNV are needed, and therefore, these results need to be treated with caution.

The OCTA images in our series showed more artifacts in eyes with CoNV in the presence of scarring or exudates. Also, the signal strength index of the OCTA images was lower in our cohort than previously reported in two studies (26.4 ± 9.8 vs. 38 ± 14 and 36.95 ± 13.97, respectively), possibly due to differences of clinical presentation of CoNV and the cooperation of patients, which may have also influenced our results. It is of note that to obtain good images patients need to maintain fixation for several seconds, which they at times found difficult.

A main disadvantage of the current AngioVue OCTA system, however, is the limited field of view, which is restricted to 6 × 6 mm. In seven eyes, it was not possible to image the full extent of CoNV with a single scan (Fig. 5B). This is an important requirement particularly for monitoring disease, which is achieved with ICGA by the use of different angle lenses with the Heidelberg Spectralis system, thereby allowing flexible field of view adjustments during the imaging process. A similar process would be indicated for OCTA to make OCTA images comparable.

Although conventional fluorescence angiography (FA and ICGA) has shown to be a very useful imaging technique to quantitatively and functionally assess CoNV, lymphatic, and ghost vessels it has several disadvantages. It is time consuming and requires intravenous dye injection, it is contraindicated in pregnant patients or patients with significantly impaired liver and kidney function, and it may cause adverse events such as nausea and less commonly allergic or anaphylactic reactions. In contrast, the potential advantages of noncontact and dye-free OCTA are obvious: the technique allows rapid angiographic image acquisition, is easy to use, and avoids the need for cannulation and the risk of dye-associated side effects. Although not capable of differentiating between active and inactive vessels and to identify afferent efferent vessels as in the case of conventional fluorescence (FA and ICG) angiography, OCTA enables three-dimensional imaging with more depth information than conventional fluorescence angiography, thus potentially providing more objective information on the localisation of CoNV. This may be important for monitoring purposes and of benefit when planning for surgical procedures such as diathermy or anterior lamellar keratoplasty. Although stereo images using ICGA and or FA provides some depth information, they are not easily quantifiable.

A key advantage of OCTA may be its suitability for serial angiographic imaging. A recent case series compared before and after treatment imaging after a variety of interventions and reported promising results that support the potential role of OCTA for monitoring changes in corneal vascular areas. Moreover, OCTA may be used to quantify flow rates of erythrocytes within vessels in neovascular networks as a novel objective biomarker for assessing CoNV. At present, OCTA is limited by methodological and technical issues, described above, causing vessel duplication, residual motion lines and vessel discontinuity, compared with convention angiography, that often make the OCTA images difficult to interpret. The most striking artifacts present in all the OCTA images are line artifacts. If the patient moves, or blinks, during a B-scan (fast axis), the OCTA method fails and gives false motion at all positions on this plane (slow axis). The AngioVue device can collect the OCT data sets (registration of data sets will be by a proprietary algorithm) using alternate fast and slow axes leading to orthogonal line artifacts being present in some images, particularly Figure 2B. Errors in the segmentation, due to these false signals, are visible in Figure 5 bottom left.

In conclusion, OCTA is a promising new imaging technique for CoNV, but our data suggest that the current instrument on its own is not sufficient for characterizing and monitoring CoNV. Further technological improvements in OCTA and optimized image processing algorithms are needed to improve image quality and reduce projection, shadow, and motion artifacts, and software validation studies are needed. Combining OCTA with conventional fluorescence angiography in a multimodal approach, however, may improve monitoring of disease and treatment planning but this will require longitudinal studies.

Acknowledgments
Disclosure: M. Brunner, None; V. Romano, None; B. Steger, None; R. Vinciguerra, None; S. Lawman, None; B. Williams, None; N. Hicks, None; G. Czanner, None; Y. Zheng, None; C.E. Willoughby, None; S.B. Kaye, None

References
5. The Collaborative Corneal Transplantation Studies Research Group. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in...
Corneal Neovascularization: ICGA and OCTA


